1. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer
- Author
-
Christopher H. Lieu, Cathy Eng, Michael J. Overman, Hai T. Tran, Muling Mao, Lee M. Ellis, E. Lin, John V. Heymach, Jeffrey S. Morris, Scott Kopetz, and Zhi-Qin Jiang
- Subjects
Male ,Vascular Endothelial Growth Factor A ,Oncology ,medicine.medical_specialty ,Bevacizumab ,Colorectal cancer ,medicine.medical_treatment ,lcsh:Medicine ,Drug resistance ,Antibodies, Monoclonal, Humanized ,Ligands ,Disease-Free Survival ,Internal medicine ,Blood plasma ,medicine ,Humans ,Molecular Targeted Therapy ,Neoplasm Metastasis ,lcsh:Science ,Chemotherapy ,Multidisciplinary ,business.industry ,lcsh:R ,Membrane Proteins ,Middle Aged ,medicine.disease ,Regimen ,Drug Resistance, Neoplasm ,Monoclonal ,Cohort ,Immunology ,Disease Progression ,Female ,lcsh:Q ,Colorectal Neoplasms ,business ,Research Article ,medicine.drug - Abstract
Background: Circulating angiogenic factors are altered in patients with mCRC receiving bevacizumab. Evaluation of alterations in levels of VEGF ligands may provide insights into possible resistance mechanisms. Methods: PlGF, VEGF-A, VEGF-C, and VEGF-D were measured from two cohorts of patients. Sequential plasma samples were obtained from a discovery cohort of 42 patients treated with chemotherapy and bevacizumab. A validation cohort included plasma samples from a cross-sectional of 403 patients prior to chemotherapy, or after progression on a regimen with or without bevacizumab. Results: In the discovery cohort, VEGF-C was increased prior to progression and at progression (+49% and +95%, respectively, p
- Published
- 2013